The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ACST Detailed Price Forecast - CNN Money||View ACST Detailed Summary - Google Finance|
|View ACST Detailed Summary - Yahoo! Finance||View ACST Stock Research & Analysis - Zacks.com|
|View ACST Trends & Analysis - Trade-Ideas||View ACST Major Holders - Barrons|
|View ACST Call Transcripts - NASDAQ||View ACST Breaking News & Analysis - Seeking Alpha|
|View ACST Annual Report - CompanySpotlight.com||View ACST OTC Short Report - OTCShortReport.com|
|View ACST Fundamentals - TradeKing||View ACST SEC Filings - Bar Chart|
|View Historical Prices for ACST - The WSJ||View Performance/Total Return for ACST - Morningstar|
|View the Analyst Estimates for ACST - MarketWatch||View the Earnings History for ACST - CNBC|
|View the ACST Earnings - StockMarketWatch||View ACST Buy or Sell Recommendations - MacroAxis|
|View the ACST Bullish Patterns - American Bulls||View ACST Short Pain Metrics - ShortPainBot.com|
|View ACST Stock Mentions - StockTwits||View ACST Stock Mentions - PennyStockTweets|
|View ACST Stock Mentions - Twitter||View ACST Investment Forum News - Investor Hub|
|View ACST Stock Mentions - Yahoo! Message Board||View ACST Stock Mentions - Seeking Alpha|
|View Insider Transactions for ACST - SECform4.com||View Insider Transactions for ACST - Insider Cow|
|View ACST Major Holdings Summary - CNBC||View Insider Disclosure for ACST - OTC Markets|
|View Insider Transactions for ACST - Yahoo! Finance||View Institutional Holdings for ACST - NASDAQ|
|View ACST Stock Insight & Charts - FinViz.com||View ACST Investment Charts - StockCharts.com|
|View ACST Stock Overview & Charts - BarChart||View ACST User Generated Charts - Trading View|
Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
Posted on Monday June 24, 2019
LAVAL, Québec, June 24, 2019 -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research,.
Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s TRILOGY 2 trial studying CaPre in patients with severe hypertriglyceridemia has achieved 100% patient randomization. This follows the Company’s prior announcement in April 2019 that the Company’s TRILOGY 1 trial had achieved 100% patient randomization.
Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer
Posted on Thursday May 23, 2019
LAVAL, Québec, May 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has completed the previously disclosed issuance of 900,000 common shares from treasury to its former chief executive officer (the “Former CEO”) pursuant to the terms of a settlement agreement announced by the Company on May 10, 2019. Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk.
Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
Posted on Tuesday May 21, 2019
LAVAL, Québec, May 21, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22nd, at 9:00 AM, PST. The conference is being held May 22-23, 2019 at The Beverly Hilton in Beverly Hills, California. Jan D’Alvise, Chief Executive Officer of Acasti, will be presenting a company overview as well as meeting with investors.